CN116019964B - Processing technology of medical dressing - Google Patents
Processing technology of medical dressing Download PDFInfo
- Publication number
- CN116019964B CN116019964B CN202211660205.3A CN202211660205A CN116019964B CN 116019964 B CN116019964 B CN 116019964B CN 202211660205 A CN202211660205 A CN 202211660205A CN 116019964 B CN116019964 B CN 116019964B
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- solution
- aqueous solution
- dressing
- alginate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012545 processing Methods 0.000 title claims abstract description 19
- 238000005516 engineering process Methods 0.000 title claims abstract description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 116
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 116
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 116
- 239000000243 solution Substances 0.000 claims abstract description 91
- 239000007864 aqueous solution Substances 0.000 claims abstract description 71
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000002156 mixing Methods 0.000 claims abstract description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 26
- 108010039918 Polylysine Proteins 0.000 claims abstract description 25
- 229920000656 polylysine Polymers 0.000 claims abstract description 25
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000011049 filling Methods 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 13
- 230000001954 sterilising effect Effects 0.000 claims abstract description 13
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 12
- 229960000458 allantoin Drugs 0.000 claims abstract description 12
- 239000012153 distilled water Substances 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 11
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims abstract description 10
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960002510 mandelic acid Drugs 0.000 claims abstract description 10
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 37
- 230000008569 process Effects 0.000 claims description 35
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 22
- 239000000661 sodium alginate Substances 0.000 claims description 22
- 235000010413 sodium alginate Nutrition 0.000 claims description 22
- 229940005550 sodium alginate Drugs 0.000 claims description 22
- 239000004745 nonwoven fabric Substances 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 16
- 239000000758 substrate Substances 0.000 claims description 16
- 235000010443 alginic acid Nutrition 0.000 claims description 13
- 229920000615 alginic acid Polymers 0.000 claims description 13
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 11
- 229940072056 alginate Drugs 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 239000010445 mica Substances 0.000 claims description 8
- 229910052618 mica group Inorganic materials 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 239000002562 thickening agent Substances 0.000 claims description 8
- 229940099259 vaseline Drugs 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 238000001125 extrusion Methods 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 239000000648 calcium alginate Substances 0.000 claims description 2
- 235000010410 calcium alginate Nutrition 0.000 claims description 2
- 229960002681 calcium alginate Drugs 0.000 claims description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 235000016804 zinc Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002829 reductive effect Effects 0.000 abstract description 8
- 230000007794 irritation Effects 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 206010052428 Wound Diseases 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 7
- 208000002874 Acne Vulgaris Diseases 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 6
- 208000028990 Skin injury Diseases 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 4
- 241000212749 Zesius chrysomallus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229920002749 Bacterial cellulose Polymers 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000223252 Rhodotorula Species 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 239000005016 bacterial cellulose Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000013354 porous framework Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field related to medical dressings, in particular to a processing technology of a medical dressing, which comprises the following steps: 1) Preparing an aqueous solution of hyaluronic acid in a mixing mode according to mass percentage, wherein the aqueous solution of hyaluronic acid is 0.5-2% of hyaluronic acid, 12-20% of glycerol and 2-5% of polylysine, and the balance is distilled water; 2) Mixing 40-60% of mandelic acid, 20-30% of nicotinamide, 10-25% of allantoin and 5-10% of polylysine according to the mass percentage to prepare a solution A; 3) Filtering and defoaming the aqueous solution of hyaluronic acid and the solution A respectively, and sterilizing by adopting high-temperature steam; 4) Respectively filling the sterilized hyaluronic acid aqueous solution and the sterilized solution A into two different dressing chambers of the same mask bag; the service life can be effectively prolonged by means of split charging and nitrogen filling, and meanwhile the irritation to the skin can be reduced.
Description
Technical Field
The invention relates to the technical field related to medical dressings, in particular to a processing technology of a medical dressing.
Background
The repair of human skin injury is a complex physiological process, the healing speed of wounds, the formation and proliferation of scars after healing, and relates to the reconstruction and regeneration of extracellular matrixes by various cells and secretion products. It mainly comprises 3 key stages: inflammatory, proliferative and reconstructive phases. For this reason, efforts have been made to find ideal applications, including good biocompatibility, control and absorption of wound exudates, prevention of bacterial invasion and inhibition of bacterial growth and proliferation, protection of new tissues, acceleration of wound healing, prevention and reduction of scars, hemostasis and analgesia, good mechanical properties, etc.
With the development of molecular biology, the application research of biological materials in medical dressings is increasing, and a great deal of results are achieved, such as hyaluronic acid, which is also called hyaluronic acid, is a biological polysaccharide, which is one of the main components of skin tissues, and can participate in each stage of repairing human skin injury: in the inflammatory phase, the synthesis of long-chain hyaluronic acid is increased, the water absorption of the long-chain hyaluronic acid causes the expansion of tissues around a wound surface, a porous framework suitable for migration of cells to the injured part is generated, the migration of neutrophils can be inhibited, and inflammatory reaction is reduced. Short chain hyaluronic acid (containing 6-20 monosaccharides) can promote fibroblast migration to wound tissues during proliferation, and the fibroblast generates collagen and glycosaminoglycan (GAG) to construct a new extracellular matrix (ECM); hyaluronic acid also promotes angiogenesis and keratinocyte proliferation and migration. During the remodeling stage, hyaluronic acid promotes normal and pathological scarring. In summary, hyaluronic acid plays a very important role in various phases of wound healing.
In the traditional processing technology of the medical dressing, the hyaluronic acid aqueous solution and other auxiliary solutions are directly mixed together for filling, so that the added preservative has strong irritation and is not beneficial to repairing skin injury in order to prolong the service life.
Disclosure of Invention
The invention aims to provide a processing technology of a medical dressing, which aims to solve the problems in the background technology.
In order to achieve the above purpose, the present invention provides the following technical solutions: a process for processing a medical dressing, comprising the steps of:
preparing an aqueous solution of hyaluronic acid in a mixing mode according to mass percentage, wherein the aqueous solution of hyaluronic acid is 0.5-2% of hyaluronic acid, 12-20% of glycerol and 2-5% of polylysine, and the balance is distilled water;
mixing 40-60% of mandelic acid, 20-30% of nicotinamide, 10-25% of allantoin and 5-10% of polylysine according to the mass percentage to prepare a solution A;
filtering and defoaming the aqueous solution of hyaluronic acid and the solution A respectively, and sterilizing by adopting high-temperature steam;
respectively filling the sterilized hyaluronic acid aqueous solution and the sterilized solution A into two different dressing chambers of the same mask bag;
and (3) filling nitrogen into dressing chambers filled with hyaluronic acid aqueous solution and solution A respectively, and sealing the mask bag to obtain the medical dressing.
The application further comprises the following technical scheme: preparing a solution B from 40 to 55 mass percent of mica, 10 to 25 mass percent of collagen and 15 to 35 mass percent of vaseline by a mixing mode; and (3) taking the solution B with the ratio of 1:0.2-1 to the aqueous solution of hyaluronic acid, adding the solution B in the process of stirring the aqueous solution of hyaluronic acid, and filtering and defoaming the aqueous solution of hyaluronic acid mixed with the solution B.
The application further comprises the following technical scheme: taking a thickening agent with the ratio of 1:0.1-0.5 to the aqueous solution of hyaluronic acid, and adding the thickening agent a small amount of times in the process of slowly stirring the aqueous solution of hyaluronic acid; the aqueous solution of hyaluronic acid mixed with a thickener was filtered to remove foam.
The application further comprises the following technical scheme: the thickener comprises carbomers, 1, 4-butanediol diglycidyl ether and/or alginate.
The application further comprises the following technical scheme: the alginate is a salt formed by alginic acid and metal ions, and is specifically one or a combination of more of sodium alginate, calcium alginate, zinc alginate, copper alginate, iron alginate and magnesium alginate.
The application further comprises the following technical scheme: also included is a substrate for adsorbing aqueous hyaluronic acid and a solution.
The application further comprises the following technical scheme: the substrate comprises cellular cellulose, the cellular cellulose is added into aqueous solution of hyaluronic acid to be stirred and mixed, and 0.5-1% of the cellular cellulose, 0.5-2% of hyaluronic acid, 12-20% of glycerol, 2-5% of polylysine and the balance of distilled water are taken according to mass percentage to be stirred and mixed.
The application further comprises the following technical scheme: the base material still includes non-woven fabrics or silk, puts into the base material cavity of facial mask bag after disinfecting non-woven fabrics or silk, can communicate dressing cavity and base material cavity through the mode of extrusion.
The application further comprises the following technical scheme: the non-woven fabric is degradable or non-degradable.
Compared with the prior art, the technical scheme provided by the invention has the following beneficial effects:
1. the invention can effectively prolong the service life by means of split charging and filling the nitrogen, and simultaneously can reduce the stimulation to the skin, and the filled nitrogen is convenient for a user to squeeze the solution A into the hyaluronic acid aqueous solution when in use, thereby improving the convenience of use; solves the problems that the traditional medical dressing processing technology directly mixes the hyaluronic acid aqueous solution with other auxiliary solutions for filling, the antiseptic required to be added has stronger irritation and is not beneficial to the repair of skin injury.
2. The medical dressing has better bacteriostasis and air permeability by using the cellulose as a substrate to adsorb the hyaluronic acid aqueous solution and adding the polylysine.
Detailed Description
The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art without making any inventive effort, based on the embodiments of the present invention are within the scope of the present invention, and the present invention is further described below with reference to the embodiments.
Example 1
A process for processing a medical dressing, comprising the steps of:
1) Preparing an aqueous solution of hyaluronic acid in a mixing manner according to the mass percentage, wherein the aqueous solution of hyaluronic acid is 0.5% of hyaluronic acid, 12% of glycerol and 2% of polylysine, and the balance is distilled water;
2) Taking sodium alginate with the ratio of 1:0.1 to the aqueous solution of hyaluronic acid, and adding sodium alginate for a small amount of times in the process of slowly stirring the aqueous solution of hyaluronic acid;
3) Preparing a solution B by mixing 40% of mica, 25% of collagen and 35% of vaseline according to the mass percentage;
4) Taking a solution B with the ratio of 1:0.5 to the aqueous solution of hyaluronic acid after adding sodium alginate, and adding the solution B in the process of stirring the aqueous solution of hyaluronic acid; obtaining a hyaluronic acid solution;
5) Mixing 50% of mandelic acid, 20% of nicotinamide, 25% of allantoin and 5% of polylysine according to the mass percentage to prepare a solution A;
6) Filtering and defoaming the hyaluronic acid solution and the solution A respectively, and sterilizing by adopting high-temperature steam;
7) Respectively filling the sterilized hyaluronic acid solution and the sterilized solution A into two different dressing chambers of the same mask bag;
8) Taking degradable non-woven fabrics, sterilizing by high temperature and ultraviolet rays, and then placing the non-woven fabrics into a substrate cavity of a mask bag;
9) And (3) filling nitrogen into dressing chambers filled with hyaluronic acid aqueous solution and solution A respectively, and sealing the mask bag to obtain the medical dressing.
Example 2
A process for processing a medical dressing, comprising the steps of:
1) Preparing an aqueous solution of hyaluronic acid in a mixing manner according to the mass percentage, wherein the aqueous solution of hyaluronic acid is 2% of hyaluronic acid, 20% of glycerol and 2% of polylysine, and the balance is distilled water;
2) Taking sodium alginate with the ratio of 1:0.1 to the aqueous solution of hyaluronic acid, and adding sodium alginate for a small amount of times in the process of slowly stirring the aqueous solution of hyaluronic acid;
3) Preparing a solution B by mixing 40% of mica, 25% of collagen and 35% of vaseline according to the mass percentage;
4) Taking a solution B with the ratio of 1:0.5 to the aqueous solution of hyaluronic acid after adding sodium alginate, and adding the solution B in the process of stirring the aqueous solution of hyaluronic acid; obtaining a hyaluronic acid solution;
5) Mixing 50% of mandelic acid, 20% of nicotinamide, 25% of allantoin and 5% of polylysine according to the mass percentage to prepare a solution A;
6) Filtering and defoaming the hyaluronic acid solution and the solution A respectively, and sterilizing by adopting high-temperature steam;
7) Respectively filling the sterilized hyaluronic acid solution and the sterilized solution A into two different dressing chambers of the same mask bag;
8) Taking degradable non-woven fabrics, sterilizing by high temperature and ultraviolet rays, and then placing the non-woven fabrics into a substrate cavity of a mask bag;
9) And (3) filling nitrogen into dressing chambers filled with hyaluronic acid aqueous solution and solution A respectively, and sealing the mask bag to obtain the medical dressing.
Example 3
A process for processing a medical dressing, comprising the steps of:
1) Preparing an aqueous solution of hyaluronic acid in a mixing manner according to the mass percentage, wherein the aqueous solution of hyaluronic acid is 1.5% of hyaluronic acid, 15% of glycerol and 2% of polylysine, and the balance is distilled water;
2) Taking sodium alginate with the ratio of 1:0.1 to the aqueous solution of hyaluronic acid, and adding sodium alginate for a small amount of times in the process of slowly stirring the aqueous solution of hyaluronic acid;
3) Preparing a solution B by mixing 40% of mica, 25% of collagen and 35% of vaseline according to the mass percentage;
4) Taking a solution B with the ratio of 1:0.5 to the aqueous solution of hyaluronic acid after adding sodium alginate, and adding the solution B in the process of stirring the aqueous solution of hyaluronic acid; obtaining a hyaluronic acid solution;
5) Mixing 50% of mandelic acid, 20% of nicotinamide, 25% of allantoin and 5% of polylysine according to the mass percentage to prepare a solution A;
6) Filtering and defoaming the hyaluronic acid solution and the solution A respectively, and sterilizing by adopting high-temperature steam;
7) Respectively filling the sterilized hyaluronic acid solution and the sterilized solution A into two different dressing chambers of the same mask bag;
8) Taking degradable non-woven fabrics, sterilizing by high temperature and ultraviolet rays, and then placing the non-woven fabrics into a substrate cavity of a mask bag;
9) And (3) filling nitrogen into dressing chambers filled with hyaluronic acid aqueous solution and solution A respectively, and sealing the mask bag to obtain the medical dressing.
Example 4
A process for processing a medical dressing, comprising the steps of:
1) Preparing an aqueous solution of hyaluronic acid in a mixing manner according to the mass percentage, wherein the aqueous solution of hyaluronic acid is 2% of hyaluronic acid, 20% of glycerol, 2% of polylysine and 0.8% of cellulose, and the balance is distilled water;
2) Taking sodium alginate with the ratio of 1:0.5 to the aqueous solution of hyaluronic acid, and adding sodium alginate a small amount of times in the process of slowly stirring the aqueous solution of hyaluronic acid;
3) 55% of mica, 10% of collagen and 35% of vaseline are prepared into a solution B in a mixing manner according to the mass percentage;
4) Taking a solution B with the ratio of 1:0.5 to the aqueous solution of hyaluronic acid after adding sodium alginate, and adding the solution B in the process of stirring the aqueous solution of hyaluronic acid; obtaining a hyaluronic acid solution;
5) Mixing 50% of mandelic acid, 20% of nicotinamide, 25% of allantoin and 5% of polylysine according to the mass percentage to prepare a solution A;
6) Filtering and defoaming the hyaluronic acid solution and the solution A respectively, and sterilizing by adopting high-temperature steam;
7) And respectively filling the sterilized hyaluronic acid solution and the sterilized solution A into two different dressing cavities of the same mask bag, and sealing the mask bag to obtain the medical dressing for direct smearing.
Example 5
A process for processing a medical dressing, comprising the steps of:
1) Preparing an aqueous solution of hyaluronic acid in a mixing manner according to the mass percentage, wherein the aqueous solution of hyaluronic acid is 0.5% of hyaluronic acid, 20% of glycerol, 5% of polylysine and 0.8% of cellulose, and the balance is distilled water;
2) Taking sodium alginate with the ratio of 1:0.5 to the aqueous solution of hyaluronic acid, and adding sodium alginate a small amount of times in the process of slowly stirring the aqueous solution of hyaluronic acid;
3) 55% of mica, 10% of collagen and 35% of vaseline are prepared into a solution B in a mixing manner according to the mass percentage;
4) Taking a solution B with the ratio of 1:0.5 to the aqueous solution of hyaluronic acid after adding sodium alginate, and adding the solution B in the process of stirring the aqueous solution of hyaluronic acid; obtaining a hyaluronic acid solution;
5) Mixing 50% of mandelic acid, 20% of nicotinamide, 25% of allantoin and 5% of polylysine according to the mass percentage to prepare a solution A;
6) Filtering and defoaming the hyaluronic acid solution and the solution A respectively, and sterilizing by adopting high-temperature steam;
7) Respectively filling the sterilized hyaluronic acid solution and the sterilized solution A into two different dressing chambers of the same mask bag; and sealing the mask bag to obtain the direct-smearing medical dressing.
Example 6
A process for processing a medical dressing, comprising the steps of:
1) Preparing an aqueous solution of hyaluronic acid in a mixing manner according to the mass percentage, wherein the aqueous solution of hyaluronic acid is 2% of hyaluronic acid, 20% of glycerol, 5% of polylysine and 0.8% of cellulose, and the balance is distilled water;
2) Taking sodium alginate with the ratio of 1:0.1 to the aqueous solution of hyaluronic acid, and adding sodium alginate for a small amount of times in the process of slowly stirring the aqueous solution of hyaluronic acid;
3) Preparing a solution B by mixing 40% of mica, 25% of collagen and 35% of vaseline according to the mass percentage;
4) Taking a solution B with the ratio of 1:0.5 to the aqueous solution of hyaluronic acid after adding sodium alginate, and adding the solution B in the process of stirring the aqueous solution of hyaluronic acid; obtaining a hyaluronic acid solution;
5) Mixing 50% of mandelic acid, 20% of nicotinamide, 25% of allantoin and 5% of polylysine according to the mass percentage to prepare a solution A;
6) Mixing hyaluronic acid solution and solution A, filtering, defoaming, and sterilizing with high-temperature steam; obtaining a medical dressing;
7) Taking degradable non-woven fabrics, and sterilizing by high temperature and ultraviolet rays;
9) Placing the sterilized non-woven fabric and the medical dressing into a mask bag, filling nitrogen, and sealing the mask bag to obtain the medical dressing and the base material for medical application.
Example 7
This example describes experimental investigation of the medical dressings with a base material obtained in examples 1 to 3.
In the application of examples 1-3, the content of sodium alginate used is small, the texture of the obtained medical dressing is thin, and the medical dressing is easy to be adsorbed on the non-woven fabric so as to facilitate the non-woven fabric to absorb the dressing.
For convenient use, two dressing chambers set gradually, and two dressing chambers are located same horizontal line with the substrate cavity.
In the use process, firstly, the dressing cavity filled with the solution A is extruded, the solution A is extruded into the dressing cavity filled with the hyaluronic acid solution, the solution A and the hyaluronic acid solution are mixed through repeated pressing, a liquid dressing is obtained, finally, the liquid dressing is extruded into the substrate cavity or is extruded into the substrate cavity through a scraping blade, and after the liquid dressing and the non-woven fabric are fully fused through the pressing and mixing mode, the non-woven fabric is taken out and applied to a place needing to be applied.
It is necessary to say that, in the use process, the dressing cavity and the substrate cavity can be communicated in an extrusion mode, and the mask bag is the prior art and is not repeated herein.
For convenient use, through holes capable of penetrating five sense organs can be formed in the non-woven fabric.
In the embodiment, taking the experiment groups 1-3 as the experiment groups 1-3, taking medical application (facial patch) sold by Jiangsu Jiaaoao medical science and technology Co., ltd in the market as the control group, carrying out scar repair test on volunteers with facial acne, wherein 20 men and women are respectively divided into four groups at random with the age of 18-35 years, 10 people in each group, wherein three groups are respectively the experiment groups 1-3, the other group is the control group, the face is applied for 15min each day by adopting non-woven fabrics adhered with the medical dressing, the continuous use is carried out for 15 days, photographing recording is carried out on the days 0, 3, 5, 10 and 15, and finally grading is carried out according to the degree of erythema/pigment change from 0 to 6 by a comparison mode, wherein 0 represents that under natural light, erythema/pigment is reduced by 1/4;2 is the observation under natural light, and the red spot/pigment is reduced by 2/4; the 4-point represents that the red spot/pigment is reduced by 3/4 when observed under natural light; 6 points represent that the red spots/pigment are basically completely reduced when observed under natural light; the scoring results for acne scar repair are shown in table 1.
Table 1 scoring table for acne scar repair
| Score \group | Experiment group 1 | Experiment group 2 | Experiment group 3 | Control group 4 |
| 0 point | 1 | 0 | 0 | 1 |
| 2 minutes | 2 | 0 | 1 | 4 |
| 4 minutes | 4 | 2 | 4 | 3 |
| 6 minutes | 3 | 8 | 5 | 2 |
Example 8
In this example, the medical dressings obtained in examples 4 to 5 were experimentally studied.
In the application of examples 4-5, the sodium alginate content was high, and the resulting medical dressing was thick in texture, so that the medical dressing could be directly applied to the skin, and the whole application could be removed from the skin after the use.
In the using process, the solution A is extruded into a dressing cavity filled with hyaluronic acid solution, the solution A and the hyaluronic acid solution are mixed through repeated pressing, and the medical dressing is obtained, and the medical dressing is directly smeared on skin when in use.
In the embodiment, taking an experiment group 4-5 as an experiment group, taking a sodium hyaluronate liquid dressing (spray) sold by Jiangsu Jiao medical science and technology Co., ltd in the market as a control group, carrying out scar repair tests on volunteers with superficial skin injuries (such as dry lacerations, bruises and vaccinia damage), wherein 15 men and women are aged between 18 years and 35 years, randomly dividing into three groups, 10 persons in each group, wherein two groups are respectively the experiment group 4-5, the other group is the control group, directly smearing a proper amount of medical dressing of the experiment group 4-5 on the surface of the wound after cleaning the wound or the affected part and drying the wound, taking sodium hyaluronate liquid dressing of the control group to be smeared on the surface of the wound once every 6-8 hours, continuously using for 15 days, carrying out photographing records on the days 0, 3, 5, 10 days and 15 days, and finally grading the change of the wound surface from 0 to 5 minutes by a comparison mode, wherein the 0 minutes represents natural light of the wound surface, and observing the wound surface to reduce 1/3;3 is observed under natural light, and the wound area is reduced by 2/3;5 points represent observation under natural light, and the reduction of the wound surface area is basically and completely reduced; the scoring results for wound area repair are shown in table 2.
Table 2 evaluation chart for wound area repair
| Score \group | Experiment group 4 | Experiment group 5 | Control group 4 |
| 0 point | 0 | 1 | 2 |
| 3 minutes | 2 | 4 | 6 |
| 5 minutes | 8 | 5 | 2 |
As shown in tables 1-2, the composition further promoted the restoration of acne after the addition of mandelic acid, nicotinamide and allantoin, and the restoration of wound surface and acne was also improved by the high content of hyaluronic acid.
Example 9
This example is an experimental study of the shelf life of the medical dressings with a substrate obtained in example 1 and example 6.
The specific gravity of the raw materials in example 1 and example 2 was unchanged, the raw materials were changed in the processing process, and in example 1, after preliminary processing in the factory, further processing was required by the user before use, and a hyaluronic acid liquid dressing was mixed with the a solution as experiment group 1; example 6 all raw materials were mixed directly prior to bagging as experimental group 6; the final nitrogen charge step was also subtracted from example 6 to serve as a control.
In this example, the life of experimental group 1, example 6 and control group was studied, and it was found that the life of experimental group 1 > experimental group 6 was larger than that of control group after the study.
It is thus found that the packaging method can effectively prolong the service life and reduce the skin irritation, and the nitrogen filling method can further promote the service life.
The nitrogen is an inert antibacterial gas, and the filled nitrogen can inhibit the growth and propagation of bacteria, so that the shelf life is prolonged.
Allantoin has physiological functions of promoting cell growth, accelerating wound healing, softening keratin, etc., and can relieve xerosis cutis, skin ulcer, acne, etc. Allantoin can keep skin moisture, moisten and soften, and has effects of protecting tissue, hydrophilizing, absorbing water, preventing water from dispersing, promoting tissue growth, promoting cell metabolism, and softening horny layer protein.
Bacterial cellulose forms a unique texture structure and has the characteristics of high water absorption, high water retention, high transmittance to liquid and gas, high wet strength, in-situ processing and forming in a wet state and the like due to a nano effect. Bacterial cellulose has good biocompatibility, high mechanical strength in wet state, good liquid and gas permeability and skin infection inhibition, and can be used as artificial skin for temporary bandaging of wounds.
Polylysine is a polypeptide with antibacterial effect, polylysine can be decomposed into lysine in human body, and lysine is one of 8 amino acids necessary for human body, and is often used for food preservation, and has wide antibacterial spectrum, and can be used for candida acuminata, rhodotorula falciparum, pichia pastoris and rhodosporidium roseum of Saccharomyces; bacillus stearothermophilus, bacillus coagulans and bacillus subtilis among gram positive bacteria; the Arthrobacter aerogenes and the escherichia coli in gram-negative bacteria have obvious inhibition and killing effects. Polylysine has a remarkable inhibitory effect on the growth of gram-positive micrococcus, lactobacillus bulgaricus, streptococcus pyogenes, gram-negative escherichia coli, salmonella and yeast.
The cellulose is used as a base material to adsorb hyaluronic acid and polylysine is added. Can lead the medical dressing to have better bacteriostasis and air permeability.
The invention and its embodiments have been described above by way of illustration and not limitation. Therefore, if one of ordinary skill in the art is informed by this disclosure, the structural mode and the embodiments similar to the technical scheme are not creatively designed without departing from the gist of the present invention.
Furthermore, it should be understood that although the present disclosure describes embodiments, not every embodiment is provided with a separate embodiment, and that this description is provided for clarity only, and that the disclosure is not limited to the embodiments described in detail below, and that the embodiments described in the examples may be combined as appropriate to form other embodiments that will be apparent to those skilled in the art.
Claims (9)
1. The processing technology of the medical dressing is characterized by comprising the following steps of:
1) Preparing an aqueous solution of hyaluronic acid in a mixing mode according to mass percentage, wherein the aqueous solution of hyaluronic acid is 0.5-2% of hyaluronic acid, 12-20% of glycerol and 2-5% of polylysine, and the balance is distilled water;
2) Mixing 40-60% of mandelic acid, 20-30% of nicotinamide, 10-25% of allantoin and 5-10% of polylysine according to the mass percentage to prepare a solution A;
3) Filtering and defoaming the aqueous solution of hyaluronic acid and the solution A respectively, and sterilizing by adopting high-temperature steam;
4) Respectively filling the sterilized hyaluronic acid aqueous solution and the sterilized solution A into two different dressing chambers of the same mask bag;
5) And (3) filling nitrogen into dressing chambers filled with hyaluronic acid aqueous solution and solution A respectively, and sealing the mask bag to obtain the medical dressing.
2. The process for manufacturing a medical dressing according to claim 1, further comprising the steps of:
1) Preparing a solution B from 40 to 55 mass percent of mica, 10 to 25 mass percent of collagen and 15 to 35 mass percent of vaseline by a mixing mode;
2) And (3) taking the solution B with the ratio of 1:0.2-1 to the aqueous solution of hyaluronic acid, adding the solution B in the process of stirring the aqueous solution of hyaluronic acid, and filtering and defoaming the aqueous solution of hyaluronic acid mixed with the solution B.
3. A process for manufacturing a medical dressing according to claim 2, further comprising the steps of: taking a thickening agent with the ratio of 1:0.1-0.5 to the aqueous solution of hyaluronic acid, and adding the thickening agent a small amount of times in the process of slowly stirring the aqueous solution of hyaluronic acid; the aqueous solution of hyaluronic acid mixed with a thickener was filtered to remove foam.
4. A process for the manufacture of a medical dressing according to claim 3, wherein the thickening agent comprises carbomers and/or alginates.
5. The process of claim 4, wherein the alginate is one or more of sodium alginate, calcium alginate, zinc alginate, copper alginate, iron alginate, and magnesium alginate.
6. The process of any one of claims 1 to 5, further comprising a substrate for adsorbing aqueous hyaluronic acid and a solution.
7. The process according to claim 6, wherein the substrate comprises cellular cellulose, the cellular cellulose is added into aqueous solution of hyaluronic acid and stirred and mixed, and the cellular cellulose is 0.5% -1%, the hyaluronic acid is 0.5% -2%, the glycerin is 12% -20%, the polylysine is 2% -5%, and the balance is distilled water and stirred and mixed.
8. The process according to claim 6, wherein the substrate further comprises a nonwoven fabric or silk, the nonwoven fabric or silk is sterilized and then put into the substrate chamber of the mask bag, and the dressing chamber and the substrate chamber can be communicated by extrusion.
9. The process of claim 8, wherein the nonwoven fabric is a degradable or non-degradable nonwoven fabric.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211660205.3A CN116019964B (en) | 2022-12-23 | 2022-12-23 | Processing technology of medical dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211660205.3A CN116019964B (en) | 2022-12-23 | 2022-12-23 | Processing technology of medical dressing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116019964A CN116019964A (en) | 2023-04-28 |
| CN116019964B true CN116019964B (en) | 2024-03-15 |
Family
ID=86077046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211660205.3A Active CN116019964B (en) | 2022-12-23 | 2022-12-23 | Processing technology of medical dressing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116019964B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998050005A1 (en) * | 1997-05-09 | 1998-11-12 | Medlogic Global Corporation | Compositions for cosmetic applications |
| CN108743430A (en) * | 2018-06-28 | 2018-11-06 | 武汉百思凯瑞生物科技有限公司 | A kind of total conveying nano-composition of Symwhite-337 and its preparation method and application |
| CN110339118A (en) * | 2019-08-19 | 2019-10-18 | 广州明辉化妆品有限公司 | Has effects that the skin whitener of skin whitening, moisturizing |
| CN114667129A (en) * | 2019-09-25 | 2022-06-24 | 莱雅公司 | Kit for caring for keratin materials |
-
2022
- 2022-12-23 CN CN202211660205.3A patent/CN116019964B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998050005A1 (en) * | 1997-05-09 | 1998-11-12 | Medlogic Global Corporation | Compositions for cosmetic applications |
| CN108743430A (en) * | 2018-06-28 | 2018-11-06 | 武汉百思凯瑞生物科技有限公司 | A kind of total conveying nano-composition of Symwhite-337 and its preparation method and application |
| CN110339118A (en) * | 2019-08-19 | 2019-10-18 | 广州明辉化妆品有限公司 | Has effects that the skin whitener of skin whitening, moisturizing |
| CN114667129A (en) * | 2019-09-25 | 2022-06-24 | 莱雅公司 | Kit for caring for keratin materials |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116019964A (en) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100676937B1 (en) | Water soluble film for skin care and wound repair and method for their preparation | |
| AU2009299453B2 (en) | Interface layer wound dressing | |
| EP3695855A1 (en) | Alginate wound repair dressing and preparation method thereof | |
| JP2617260B2 (en) | Gel composition for wound treatment | |
| KR20210008351A (en) | Wound dressing to treat damaged skin | |
| KR101548752B1 (en) | Novel active ingredient in cicatrization and use thereof | |
| CN109847088B (en) | Composite acellular dermal matrix biological dressing and preparation method thereof | |
| CN112336912B (en) | Monoatomic antibacterial disinfecting hemostatic hydrogel and preparation method thereof | |
| CN103159967A (en) | Preparation method of collagen-based sponge wound dressing with self-anti-inflammatory function | |
| CN110859989B (en) | Liquid band-aid and preparation method thereof | |
| CN114099476A (en) | Functional gel layer, scar patch and preparation method thereof | |
| CN111135154B (en) | Anti-aging bacterial cellulose membrane and preparation method thereof | |
| CA2155518A1 (en) | Pharmaceutical compositions comprising a spongy material consisting of ester derivatives of hyarulonic acid combined with other pharmacologically active substances | |
| Chen et al. | The role of gel wound dressings loaded with stem cells in the treatment of diabetic foot ulcers | |
| CN116019964B (en) | Processing technology of medical dressing | |
| CN111012944A (en) | Liquid dressing based on alginate and hyaluronic acid and preparation method thereof | |
| CN115068367B (en) | Gel special for beauty instrument and preparation method thereof | |
| KR102321066B1 (en) | Composition containing beta-glucan, glycitin, and 4',6,7-Trimethoxyisoflavone for wound-healing or skin activation | |
| CN111870590B (en) | Liquid acne-removing patch and preparation method thereof | |
| CN114848884A (en) | Polyurethane foam dressing and preparation method thereof | |
| KR101576244B1 (en) | aloin loaded wound dressing composition based on hydrogel and manufacturing method thereof | |
| CN112354006A (en) | Preparation method of acellular amniotic membrane hydrogel dressing added with ozone oil | |
| CN115678048B (en) | Injectable composite hydrogel capable of promoting wound healing and reducing scar formation, and preparation method and application thereof | |
| RU2804197C1 (en) | Biologically active material for covering wound surfaces | |
| CN116440066A (en) | Hydrogel for wound repair and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |